Melatonin MT 1/2 receptor stimulation reduces cortical overflow of cholecystokinin-like material in a model of anticipation of social defeat in the rat

Neuropharmacology

Volumn 46, Issue 8, 2004, Pages 1158-1167

  Becker, Chrystel ^a   Andre, Judith ^a   Zeau, Brigitte ^a   Rettori, Marie Claire ^b   Guardiola Lemaitre, Béatrice ^b   Hamon, Michel ^a   Benoliel, Jean Jacques ^a,c  

^a INSERM   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

aCSF, artificial cerebrospinal fluid; Anticipation of social defeat; Anxiety; BSA, bovine serum albumin; CCK; CCK, cholecystokinin; CCKLM, cholecystokinin like material; i.p., intraperitoneally; In vivo microdialysis; Melatonin receptor agonist; Stress

Indexed keywords

ACETAMIDE DERIVATIVE; CHOLECYSTOKININ; CHOLECYSTOKININ LIKE PEPTIDE; MELATONIN; MELATONIN RECEPTOR; S 22153;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTICIPATION; ANXIETY; ARTICLE; BODY POSTURE; DEFENSIVE BEHAVIOR; DRUG EFFECT; IMMOBILIZATION; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; STRESS; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANIMALS; ANXIETY; CEREBRAL CORTEX; CHOLECYSTOKININ; DOMINANCE-SUBORDINATION; HETEROCYCLIC COMPOUNDS, 2-RING; MALE; MELATONIN; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2;

EID: 1942468741     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.02.006     Document Type: Article

References (46)

1. Becker C., Thiébot M.H., Touitou Y., Hamon M., Cesselin F., Benoliel J.J. Enhanced cortical extracellular levels of cholecystokinin-like material in a model of anticipation of social defeat in the rat. Journal of Neuroscience. 21:2001;262-269.
2. B receptors, inhibits the release of cholecystokinin-like material from the rat spinal cord in vitro. Brain Research. 590:1992;255-262.
3. Bradwejn J., Koszycki D., Meterissian G. Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Canadian Journal of Psychiatry. 35:1990;83-85.
4. Bradwejn J., Koszycki D., Couëtoux du Tertre A., van Megen H., den Boer J., Westenberg H., Annable L. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Archives of General Psychiatry. 51:1994;486-493.
5. Coventry T.L., D'Aquila P.S., Brain P., Willner P. Social influences on morphine conditioned place preference. Behavioural Pharmacology. 8:1997;575-584.
6. Daugé V., Léna I. CCK in anxiety and cognitive processes. Neuroscience and Biobehavioral Reviews. 22:1998;815-825.
7. De Montigny C. Cholecystokinin-tetrapeptide induces panic-like attacks in healthy volunteers. Archives of General Psychiatry. 46:1989;511-517.
8. Delagrange P., Guardiola-Lemaître B. Melatonin, its receptors, and relationships with biological rhythm disorders. Clinical Neuropharmacology. 20:1997;482-510.
9. Delagrange P., Ting K.N., Kopp C., Lahaye C., Lesieur D., Weibel L., Bennejean C., Renard P., Rettori M.C. In vitro and in vivo antagonist properties of S22153, a new melatonin ligand. Fundamental and Clinical Pharmacology. 13:1999;253.
10. Dubocovich, M.L., Cardinali, D.P., Guardiola, B., Hagan, R.M., Krause, D.N., Sugden, D., 1998. Melatonin receptors. IUPHAR Receptor Compendium, pp. 187-193.
11. Giraldi T., Perissin L., Zorget S., Rapozzi U., Rodani M.G. Metastasis and neuroendocrine system in stressed mice. International Journal of Neuroscience. 74:1994;265-278.
12. Goldman B.D. The physiology of melatonin in mammals. Pineal Research Reviews. 1:1983;145-182.
13. Golombek D.A., Martini M., Cardinali D.P. Melatonin as an anxiolytic in rats: time dependence and interaction with central GABAergic system. European Journal of Pharmacology. 237:1993;231-236.
14. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacology & Therapeutics. 65:1995;319-395.
15. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacology & Therapeutics. 82:1999;1-61.
16. Guardiola-Lemaître B., Lenegre A., Porsolt R.D. Combined effects of diazepam in two tests for anxiolytic activity in the mouse. Pharmacolology, Biochemistry, and Behavior. 41:1992;405-408.
17. Karsch F.J., Bittman E.L., Foster D.L., Goodman R.L., Legan S.J., Robinson J.E. Neuroendocrine basis of seasonal reproduction. Recent Progress in Hormone Research. 40:1984;185-232.
18. Kerdelhué B., Grouin J.M., Lenoir V., Schuster C., Martin A., Milhaud G., Israel L., Guardiola-Lemaître B. S 23478, a novel melatoninergic agonists inhibits DMBA-induced mammary carcinogenesis in Sprague-Dawley rats. 2003;American Association for Cancer Research. Advances in Breast Cancer Research, Huntington Beach, CA. October 2003, Abst. B30.
19. Koolhaas J.M., Hermann P.M., Kemperman C., Bohus B., van den Hoofdakker R.H., Beersma D.G.M. Single social defeat in male rats induces a gradual but long lasting behavioural change: a model of depression? Neuroscience Research Communications. 7:1990;35-41.
20. Kopp C., Vogel E., Rettori M.C., Delagrange P., Guardiola-Lemaître B., Misslin R. Effects of melatonin on neophobic responses in different strains of mice. Pharmacolology, Biochemistry, and Behavior. 63:1999a;521-526.
21. Kopp C., Vogel E., Rettori M.C., Delagrange P., Renard P., Lesieur D., Misslin R. Antagonistic effects of S22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice. Pharmacolology, Biochemistry, and Behavior. 64:1999b;131-136.
22. Kopp C., Vogel E., Rettori M.C., Delagrange P., Misslin R. Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of mt1 and/or MT2 receptors in the regulation of emotional responsiveness. Neuropharmacology. 39:2000;1865-1871.
23. Liu C., Weaver D.R., Jin X., Shearman L.P., Pieschl R.L., Gribkoff V.K., Reppert S.M. Molecular dissection of two distinct actions of melatonin on suprachiasmatic circadian clock. Neuron. 19:1997;91-102.
24. Maestroni G.J., Conti A., Pierpaoli W. Role of the pineal gland in immunity. III. Melatonin antagonizes the immunosuppressive effect of acute stress via an opiatergic mechanism. Immunology. 63:1988;465-469.
25. Marrow L.P., Overton P.G., Brain P.F. A re-evaluation of social defeat as an animal model of depression. Journal of Psychopharmacology. 13:1999;115-121.
26. Miguez J.M., Aldegunde M. Changes in the hypothalamic serotonergic function may mediate the endocrine effects of melatonin. Journal of Physiology and Biochemistry. 52:1996;239-246.
27. Miguez J.M., Martin F.J., Lena M., Aldegunde M. Changes in serotonin level and turnover in discrete hypothalamic nuclei after pinealectomy and melatonin administration to rats. Neurochemistry International. 29:1996;651-658.
28. Mocchegiani E., Perissin L., Santarelli L., Tibaldi A., Zorzet S., Rapozzi V., Giacconi R., Bulian D., Giraldi T. Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. International Journal of Immunopharmacology. 21:1999;27-46.
29. Nevo I., Becker C., Hamon M., Benoliel J.J. Stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat: prevention by diazepam but not ondansetron. Journal of Neurochemistry. 66:1996;2041-2049.
30. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M., Roques B.P. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacological Reviews. 51:1999;745-781.
31. Pappolla M.A., Ghyan Y.J., Poeggeler B., Frangione B., Wilson G., Ghiso J., Reiter R.J. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. Journal of Neural Transmission. 107:2000;203-231.
32. Paxinos P., Watson C. The Rat Brain in Stereotaxic Coordinates. second ed:1986;Academic Press, Sydney.
33. Pierrefiche G., Zerbib R., Laborit H. Anxiolytic activity of melatonin in mice : involvement of benzodiazepine receptors. Research Communications in Chemical Pathology and Pharmacology. 82:1993;131-142.
34. 2+ antagonist, on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test. International Journal of Neuropsychopharmacology. 1:1998;35-40.
35. Reiter R.J. Melatonin and human reproduction. Annals of Medicine. 30:1998;103-108.
36. Reppert S.M. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. Journal of Biological Rhythms. 12:1997;528-531.
37. Rettori M.C., Lahaye C., Howell T., Lesieur D., Renard P., Van Reeth O., Kopp C., Delagrange P. Activity of S 23478, a new melatonin agonist, in different animal models. Fundamental and Clinical Pharmacology. 13:1999;271.
38. Shlick J., Vasar E., Bradwejn J. Cholecystokinin and psychiatric disorders. Role in aetiology and potential of receptor antagonists in therapy. CNS Drugs. 8:1997;134-152.
39. Siegfried B., Frischknecht H.R., Waser P.G. Defeat, learned submissiveness, and analgesia in mice: effect of genotype. Behavioral and Neural Biology. 42:1984;91-97.
40. Studler J.M., Simon H., Cesselin F., Legrand J.C., Glowinski J., Tassin J.P. Biochemical investigation on the localization of the cholecystokinin octapeptide in dopaminergic neurons originating from the ventral tegmental area of the rat. Neuropeptides. 2:1981;131-139.
41. Tidey J.W., Miczek K.A. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Research. 721:1996;140-149.
42. Tornatzky W., Miczek K.A. Long-term impairment of automomic circadian rhythms after brief intermittent social stress. Physiology and Behavior. 53:1993;983-993.
43. Tornatzky W., Miczek K.A. Behavioral and autonomic responses to intermittent social stress: differential effects of clonidine and metoprolol. Psychopharmacology. 116:1994;346-356.
44. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Kahn R.S. Cholecystokinin in anxiety. European Neuropsychopharmacology. 6:1996;263-280.
45. Vivian J.A., Miczek K.A. Diazepam and gepirone selectively attenuate either 20-32 kHz or 32-64 kHz ultrasonic vocalizations during aggressive encounters. Psychopharmacology. 113:1993;66-73.
46. Weibel L., Rettori M.C., Lesieur D., Delagrange P., Renard P., Van Reeth O. A single oral dose of S22153, a melatonin antagonist, blocks the phase advancing effects of melatonin in C3H mice. Brain Reseach. 829:1999;160-166.